Slezin eye drops 3 + 1mg / ml, 15ml

The drug is applied topically. 1-2 drops are instilled into the conjunctival sac as needed.

Eye drops in the form of a clear, colorless solution.

1 ml

hypromellose 3 mg

dextran 70 1 mg

Excipients: glycerol - 2 mg, boric acid - 3 mg, sodium tetraborate decahydrate - 350 mcg, potassium chloride - 1.2 mg, sodium chloride - 6.2 mg, disodium edetate dihydrate - 500 mcg, benzalkonium chloride - 75 mcg, sodium hydroxide 1M solution or hydrochloric acid 1M solution - up to pH 7.4 ± 0.1, purified water - up to 1 ml = 1.00645 g.

• Children and adolescents under 18 years of age (there is no data on the effectiveness and safety of the drug in children);

• hypersensitivity to hypromellose, dextran or any of the auxiliary components of the drug.

pharmachologic effect

Keratoprotective drug, artificial tear. Slezin contains a water-soluble polymer system, which, in combination with the natural tear fluid of the eye, improves corneal hydration, ensuring the hydrophilicity of the corneal surface due to the usual adsorption processes at the interface between the tear fluid film and the corneal surface. The drug physiologically mixes with the tear fluid film, increasing its stability on the surface of the cornea. Reduces irritation symptoms associated with dry eye syndrome and protects the cornea from drying out. After a single instillation, the effect of the drug lasts for 90 minutes.

Pharmacokinetics

When applied topically, systemic absorption is low.

Side effect

Blurred vision has been reported most frequently in clinical trials. The following adverse events are classified according to the following frequency of occurrence: very common (> 1/10), often (> 1/100 to <1/10), infrequently (> 1/1000 to <1/100), rarely (> 1/10 000 to <1/1000), very rare (<1/10 000), frequency unknown (frequency cannot be determined from available data). Each adverse event group is listed in descending order of severity. From the immune system: frequency unknown - hypersensitivity. From the nervous system: infrequently - headache. From the side of the organ of vision: very often - blurred vision; often - residual symptoms of dry eye syndrome, eyelid disorders, unusual sensations in the eyes, feeling of a foreign body,discomfort in the eyes; infrequently - itchy eyes, eye irritation, conjunctival injection, photophobia, eye hypesthesia; the frequency is unknown - erythema of the eyelids, conjunctival edema, eye pain, discharge from the eyes, crusts on the edges of the eyelids, lacrimation. General disorders and disorders at the injection site: infrequently - discomfort on the skin.

Application during pregnancy and lactation

There is no information on the use of Slezin during pregnancy. However, the active ingredients of Slezin - dextran-70 and hypromellose - act as additional protection of the anterior surface of the eyeball and do not exhibit pharmacological activity. Absorption of the components of the drug into the systemic circulation is not expected, which excludes the possibility of their effect on reproductive function or fetal development. The use of the drug Slezin during pregnancy is possible. It is not known whether dextran-70, hypromellose or other components of the drug pass into breast milk. Despite this, it is not necessary to stop breastfeeding. The use of the drug Slezin during breastfeeding is possible. Because dextran and hypromellose are pharmacologically inert substances,the effect of Slezin on male and female fertility is not expected.

Application in children

Contraindicated in children and adolescents under the age of 18.

special instructions

The drug Slezin is intended only for topical use in ophthalmology with dry eye syndrome characterized by discomfort, dryness, burning sensation, foreign body sensation, irritation caused by air conditioning, flickering of a TV or computer monitor that has been operating for a long time, dust, smoke, ultraviolet rays, dry heat, wind and etc. The drug Slezin should not be used for injection. If the patient has a headache, eye pain, vision changes, eye irritation, persistent redness, or if the condition worsens or persists for more than 72 hours, the drug should be discontinued and a doctor should be consulted. Slezin contains benzalkonium chloride, which can irritate the eyes and discolor soft contact lenses. Contact with soft contact lenses should be avoided.When wearing contact lenses, before instilling the drug, they should be removed and reinstalled no earlier than 15 minutes after using the drug. Impact on the ability to drive vehicles and use mechanisms Temporary blurred vision or other visual impairments after using the drug may affect the ability to drive vehicles and mechanisms. If blurred vision occurs after the instillation of the drug, the patient should wait until the clarity of vision is restored before driving vehicles and mechanisms.Impact on the ability to drive vehicles and use mechanisms Temporary blurred vision or other visual impairments after using the drug may affect the ability to drive vehicles and mechanisms. If blurred vision occurs after the instillation of the drug, the patient should wait until the clarity of vision is restored before driving vehicles and mechanisms.Impact on the ability to drive vehicles and use mechanisms Temporary blurred vision or other visual impairments after using the drug may affect the ability to drive vehicles and mechanisms. If blurred vision occurs after the instillation of the drug, the patient should wait until the clarity of vision is restored before driving vehicles and mechanisms.

Overdose

Based on the available data, there have been no cases of drug overdose. Based on the characteristics of the drug Slezin, in the event of an overdose with topical application or if the contents of one bottle are accidentally swallowed, toxic effects are unlikely. In case of instillation into the conjunctival cavity of an excessive amount of the drug, it is necessary to rinse the eyes with warm water.

Drug interactions

Clinically significant drug interactions with other drugs are not expected, despite the fact that drug interaction studies have not been conducted.